Pembrolizumab Combined With Either Docetaxel or Gemcitabine in Patients With Advanced or Metastatic Platinum-Refractory Urothelial Cancer: Results From a Phase I Study

Although immune checkpoint inhibitor therapy has led to modest response rates in patients with advanced urothelial cancer, the combination of chemotherapy with immune checkpoint inhibition has not been previously clinically studied. In this phase I study, we found that the combination of pembrolizum...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Genitourin Cancer
Asıl Yazarlar: Parikh, Mamta, Pan, Chong-Xian, Beckett, Laurel A., Li, Yueju, Robles, Daniel A., Aujla, Pawandeep K., Lara, Primo N.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6450697/
https://ncbi.nlm.nih.gov/pubmed/30166228
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.clgc.2018.07.004
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller